Prelude Therapeutics Inc (PRLD): R&D Expense
$94.30M
Year ended 2025-12-31
$69.43M
Trailing 12 months to 2026-06-30
+0.5%
3-year compound annual growth
+14.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $94.30M | -20.1% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $118.00M | +14.1% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $103.39M | +11.3% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $92.89M | +7.0% | 2024-02-15, From 2022-01-01 |
| 2021-12-31 | $86.78M | +80.1% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $48.18M | +98.4% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $24.28M | n/a | 2021-03-16, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $94.30M | -20.1% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $313.0K | -52.4% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $24.97M | +50.9% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $74.04M | +15.3% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $44.49M | +11.3% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $138.09M | +868.4% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $122.0K | +3.4% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $73.70M | +25.4% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $25.24M | -53.3% |
Compare PRLD, EMMA, JAGX, EVMN side by side · Screen every company in Pharmaceutical Preparations ↗